Simulations Plus, Inc. (NASDAQ:SLP) Given Consensus Recommendation of “Hold” by Analysts

Simulations Plus, Inc. (NASDAQ:SLP) has earned a consensus recommendation of “Hold” from the ten research firms that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $25.00.

Several analysts have recently commented on the company. Citigroup reaffirmed a “market perform” rating on shares of Simulations Plus in a research report on Tuesday, January 6th. TD Cowen reissued a “hold” rating on shares of Simulations Plus in a research report on Thursday, January 8th. Zacks Research downgraded Simulations Plus from a “strong-buy” rating to a “hold” rating in a research note on Monday, February 2nd. Finally, BTIG Research lowered Simulations Plus from a “buy” rating to a “neutral” rating in a research report on Thursday, December 18th.

Institutional Trading of Simulations Plus

A number of hedge funds have recently made changes to their positions in the stock. North Star Investment Management Corp. increased its stake in shares of Simulations Plus by 195.6% during the 3rd quarter. North Star Investment Management Corp. now owns 168,130 shares of the technology company’s stock worth $2,534,000 after purchasing an additional 111,255 shares during the last quarter. Tributary Capital Management LLC lifted its stake in shares of Simulations Plus by 214.7% in the 3rd quarter. Tributary Capital Management LLC now owns 1,136,980 shares of the technology company’s stock valued at $17,134,000 after purchasing an additional 775,704 shares during the last quarter. Prescott Group Capital Management L.L.C. acquired a new stake in shares of Simulations Plus in the 2nd quarter valued at $1,396,000. Royce & Associates LP boosted its holdings in Simulations Plus by 31.6% in the third quarter. Royce & Associates LP now owns 348,758 shares of the technology company’s stock worth $5,256,000 after purchasing an additional 83,758 shares in the last quarter. Finally, Stephens Investment Management Group LLC boosted its holdings in Simulations Plus by 46.3% in the third quarter. Stephens Investment Management Group LLC now owns 392,840 shares of the technology company’s stock worth $5,920,000 after purchasing an additional 124,264 shares in the last quarter. 78.08% of the stock is owned by hedge funds and other institutional investors.

Simulations Plus Stock Performance

Shares of NASDAQ:SLP opened at $12.22 on Friday. The company has a market cap of $246.23 million, a PE ratio of -3.82 and a beta of 1.17. Simulations Plus has a 52 week low of $11.16 and a 52 week high of $36.45. The firm has a 50 day simple moving average of $16.05 and a 200 day simple moving average of $16.39.

Simulations Plus (NASDAQ:SLP) last posted its quarterly earnings data on Thursday, January 8th. The technology company reported $0.13 EPS for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.05). Simulations Plus had a positive return on equity of 14.02% and a negative net margin of 81.66%.The firm had revenue of $18.42 million during the quarter, compared to analyst estimates of $18.05 million. During the same period in the prior year, the business posted $0.17 EPS. On average, equities analysts predict that Simulations Plus will post 1.09 earnings per share for the current year.

About Simulations Plus

Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.